The delivery of voriconazole directly to the lung via inhaled formulation allows for greater efficacy and improved safety than orally administered voriconazole in asthma patients, revealed the phase-1 study for inhaled voriconazole powder conducted by TFF Pharmaceuticals.  Announcing the positive results from the study, the clinical-stage biopharmaceutical company focused on innovative drug delivery models based on its patented Thin Film Freezing (TFF) technology platform said that the inhaled  voriconazole powder improved safety through reduced systemic toxicities and reduced drug to drug interactions. The drug was found to be well tolerated in the 16-patient cohort, said the company, adding that these findings also provide hope that TFF technology will potentially help develop more therapeutic applications.